New cocktail aims to outsmart Drug-Resistant lung cancer
NCT ID NCT04285671
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether adding two antibody drugs (trastuzumab and necitumumab) to the standard pill osimertinib can shrink tumors in people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to osimertinib alone. About 30 participants will receive the combination to find the best dose and see how well it works. The goal is to overcome drug resistance and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab, necitumumab, and osimertinib
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard therapy.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply to everyone. Adding more drugs also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New drug combo aims to reboot immune system against lung cancer
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- New hope for drug-resistant lung cancer: combo therapy tested in early trial